NCT00050154View on ClinicalTrials.gov

Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

July 31, 2002

Study Completion Date

May 31, 2006

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

ZARNESTRA, tipifarnib, R115777

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00050154 - Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS) | Biotech Hunter | Biotech Hunter